Director Dealings

RNS Number : 1452L
Byotrol PLC
20 December 2018
 

 

20 December 2018

 

 

 

 

 

Byotrol plc

("Byotrol", the "Company" or the "Group")

 

Director Dealings

 

 

Byotrol plc, the AIM listed anti-microbial technology company, announces that on 20 December 2018, John Langlands, Non-Executive Chairman of the Company, and Dr Trevor Francis, Chief Technical Officer of the Company, purchased 2,400,000 and 1,559,312 ordinary shares of 0.25p each ("Ordinary Shares") respectively at a price of 1.535p and 1.6p per Ordinary Share, respectively (the "Purchases").


Following the Purchases, Mr. Langlands has an interest in 8,000,000 Ordinary Shares representing approximately 1.85 per cent. of the total voting rights of the Company and Dr Trevor Francis has an interest in 4,470,214 Ordinary Shares representing approximately 1.03 per cent. of the total voting rights of the Company.

 

 

 

Enquiries:

                                                                                                                                                     

David Traynor - Chief Executive, Byotrol plc                                                               01925 742 000

David Paton - Investor Relations                                                                                 07714 190 474

 

 

finnCap Ltd                                                                                                                   020 7220 0500
(Nominated Adviser & Broker)

Geoff Nash/Kate Bannatyne- Corporate Finance

Richard Chambers - Corporate Broking

 

 

The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.

 

Notes to Editors:

 

Byotrol plc (BYOT.L), quoted on AIM, is a specialist developer of antimicrobial technologies, identifying, developing, formulating and commercialising cutting-edge antimicrobial solutions.

 

Our patented suite of technologies deliver powerful, broad-spectrum efficacy, optimised against commonly-occurring and industry-specific pathogens.

 

Founded in 2005, the Company seeks to develop and commercialise advanced antimicrobial technologies that create easier, safer and cleaner lives for everyone.

 

For more information, please go to www.byotrol.co.uk

 

 

Accordingly, the Company makes the following announcement and notification in accordance with the EU Market Abuse Regulation (No 596/2014):

 

1.    

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

John Langlands

2.    

Reason for the Notification

a)

Position/status

Non-Executive Chairman

b)

Initial notification/Amendment

Initial

3.    

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Byotrol Plc

b)

LEI

213800AJMTSTIPA59A34

4.    

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

ordinary shares of 0.25p each

Identification code

GB00B0999995

b)

Nature of the transaction

Purchase of Ordinary Shares

c)

Price(s) and volume(s)

Volume - 2,400,000

Price - 1.535 pence

d)

Aggregated information:

See 4c) above

e)

Date of the transaction

20 December 2018

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

 

1.    

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Dr Trevor Francis

2.    

Reason for the Notification

a)

Position/status

Chief Technical Officer

b)

Initial notification/Amendment

Initial

3.    

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Byotrol Plc

b)

LEI

213800AJMTSTIPA59A34

4.    

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

ordinary shares of 0.25p each

Identification code

GB00B0999995

b)

Nature of the transaction

Purchase of Ordinary Shares

c)

Price(s) and volume(s)

Volume - 1,559,312

Price - 1.6 pence

d)

Aggregated information:

See 4c) above

e)

Date of the transaction

20 December 2018

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHPGGPUPUPRGPU
UK 100

Latest directors dealings